Tempest Therapeutics Signs Up to $50M Equity Purchase Agreement With Lincoln Park
Tempest Therapeutics entered an equity purchase agreement with Lincoln Park Capital Fund for up to $50.0 million in common stock, with an initial available amount of $25.0 million over up to 24 months. The company must file a Securities Act registration statement within 10 days. Senlang will coordinate TPST-4003 trials in China for myasthenia gravis and multiple sclerosis starting Q4 2026.